Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)

NCT04001517 is registered in ClinicalTrials.gov with EIP Pharma Inc as lead sponsor.

NCT NCT04001517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04001517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)
Lead sponsor
EIP Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2019
Completion date
June 30, 2020
Enrollment
91 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

dementia with lewy bodies (dlb)